Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma

The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduct...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pramod Savarapu, Basel Abdelazeem, Sakiru Isa, Kavitha Kesari, Arvind Kunadi
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	ipilimumab nivolumab checkpoint inhibitor immune-related adverse events ventricular tachycardia cardiotoxicity cardiomyopathy case report Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/f001346cc9f9404f9dc06899395f630d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f001346cc9f9404f9dc06899395f630d
record_format	dspace
spelling	oai:doaj.org-article:f001346cc9f9404f9dc06899395f630d2021-11-17T14:21:57ZIpilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma2000-966610.1080/20009666.2021.1965708https://doaj.org/article/f001346cc9f9404f9dc06899395f630d2021-11-01T00:00:00Zhttp://dx.doi.org/10.1080/20009666.2021.1965708https://doaj.org/toc/2000-9666The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduction abnormalities, ventricular storm, and cardiomyopathy. Cardiomyopathy is one of the significant side effects highlighted in some of the case reports. The physicians should include autoimmune toxicities as the potential differential diagnosis in patients presenting with an unusual presentation and receiving ICIs. We report a case of a 66-year-old female with advanced renal cell carcinoma who developed cardiomyopathy and ventricular tachycardia from nivolumab and ipilimumab therapy.Pramod SavarapuBasel AbdelazeemSakiru IsaKavitha KesariArvind KunadiTaylor & Francis Grouparticleipilimumabnivolumabcheckpoint inhibitorimmune-related adverse events ventricular tachycardiacardiotoxicitycardiomyopathycase reportInternal medicineRC31-1245ENJournal of Community Hospital Internal Medicine Perspectives, Vol 11, Iss 6, Pp 874-876 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ipilimumab nivolumab checkpoint inhibitor immune-related adverse events ventricular tachycardia cardiotoxicity cardiomyopathy case report Internal medicine RC31-1245
spellingShingle	ipilimumab nivolumab checkpoint inhibitor immune-related adverse events ventricular tachycardia cardiotoxicity cardiomyopathy case report Internal medicine RC31-1245 Pramod Savarapu Basel Abdelazeem Sakiru Isa Kavitha Kesari Arvind Kunadi Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
description	The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduction abnormalities, ventricular storm, and cardiomyopathy. Cardiomyopathy is one of the significant side effects highlighted in some of the case reports. The physicians should include autoimmune toxicities as the potential differential diagnosis in patients presenting with an unusual presentation and receiving ICIs. We report a case of a 66-year-old female with advanced renal cell carcinoma who developed cardiomyopathy and ventricular tachycardia from nivolumab and ipilimumab therapy.
format	article
author	Pramod Savarapu Basel Abdelazeem Sakiru Isa Kavitha Kesari Arvind Kunadi
author_facet	Pramod Savarapu Basel Abdelazeem Sakiru Isa Kavitha Kesari Arvind Kunadi
author_sort	Pramod Savarapu
title	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_short	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_full	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_fullStr	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_full_unstemmed	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_sort	ipilimumab and nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/f001346cc9f9404f9dc06899395f630d
work_keys_str_mv	AT pramodsavarapu ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma AT baselabdelazeem ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma AT sakiruisa ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma AT kavithakesari ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma AT arvindkunadi ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma
_version_	1718425519865724928

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma

Ejemplares similares